Company intelligence
bioSeedin
Connecting novel therapeutics, emerging science, and technological assets to global partners and resources.
About bioSeedin
bioSeedin is a subsidiary of ACROBiosystems Group (SHE:301080), a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. bioSeedin, one of the most preeminent asset management, public relations, and financial advisory firms for biotech and pharmaceutical companies in APAC, operates across North America, Europe, and Asia. Based on hosting the annual Biopharmaceutical Developer Innovation Conference, the largest and most influential conference in Asia, bioSeedin aggregates industrial resources across 6000 pharmaceutical enterprises worldwide. The firm provides asset management services via licensing in and out, co-developmental partner sourcing, and project implementation, as well as advising on public relation management, Asia market entry, investment strategy, mergers and acquisitions, and capital raising. bioSeedin aims to be the supreme asset transaction platform for our global clients. By facilitating R&D efficiency, maximizing research resources and funding, and emerging market access to deliver therapeutics faster and benefit our patients worldwide. If you are interested in our current assets and other services, please contact us: license@bioseedin.com; Or review our LinkedIn Posts page and check for Documents; Or visit our licensing info website https://www.bioseedin.com/licensing
Verified activity
Signals from bioSeedin
15 published signals
Customers & Market
bioSeedin highlights that since 2023, Eli Lilly has completed 23 acquisitions and 37 licensing agreements and collaboration agreements.
Reported by bioSeedin
Capital & Finance
bioSeedin's PDS Biotechnology entered into a PIPE financing arrangement for up to $22.55 million led by Nant Capital, with participation from existing investors.
Reported by bioSeedin
Capital & Finance
bioSeedin closed an oversubscribed $70 million Series B financing for Moonwalk Biosciences to advance RNAi therapies for obesity and cardiometabolic diseases.
Reported by bioSeedin
Capital & Finance
bioSeedin closed a $116 million Series A financing round led by an undisclosed private family fund and foundation to advance its CAR-T cell therapy pipeline for tumors of the central nervous system.
Reported by bioSeedin
Strategy & Corporate Development
bioSeedin announced that Sernova Biotherapeutics and Seraxis Holdings entered into a definitive merger agreement to form BetaNova Biotherapeutics, a clinical-stage regenerative medicine company focused on islet cell replacement for type 1 diabetes.
Reported by bioSeedin
Legal & Regulatory
bioSeedin announced that a Phase I small-molecule inhibitor, TP1001, is available for out-licensing targeting a fibrosis-associated GTPase upstream of MRTF-A for the treatment of chronic HFrEF and HFpEF.
Reported by bioSeedin
Capital & Finance
bioSeedin reported that Superluminal Medicines Inc. raised an oversubscribed Series B led by BVF Partners for $60 million.
Reported by bioSeedin
Capital & Finance
bioSeedin reported that NovaGo Therapeutics raised $30 million in a round led by Neurimmune and Pureos for $30 million.
Reported by bioSeedin
Capital & Finance
bioSeedin reported that Intellia Therapeutics, Inc. secured a non-dilutive senior secured debt facility from OrbiMed for $400 million.
Reported by bioSeedin
Capital & Finance
bioSeedin reported that CytoDyn Inc. announced the closing of a $16.5 million financing to support clinical development of leronlimab.
Reported by bioSeedin
Capital & Finance
bioSeedin reported that Convergen raised $15 million in Seed+ financing led by MPCi to advance its TrimTAC targeted protein degradation platform.
Reported by bioSeedin
Research & Knowledge
bioSeedin observed progress on Xaira Therapeutics regarding an AI model strat from premium data.
Reported by Kenneth Chih-Wei Chen
Strategy & Corporate Development
bioSeedin completed the acquisition of Alkeus Pharmaceuticals, Inc. for approximately $450M upfront, including $270M in cash and $180M in Tarsus stock.
Reported by bioSeedin
Presence & Recognition
bioSeedin highlights the upcoming Pharma Vista Summit 2026 virtual summit featuring 200+ global pharma and biotech leaders from 70+ companies across 25+ countries.
Reported by bioSeedin
Presence & Recognition
bioSeedin is attending the LSX Congress USA event in Boston on September.
Reported by Kenneth Chih-Wei Chen